Mrz 2549

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534785

CAS#: 84774-03-8

Description: Mrz 2549 is a bioactive chemical.


Chemical Structure

img
Mrz 2549
CAS# 84774-03-8

Theoretical Analysis

MedKoo Cat#: 534785
Name: Mrz 2549
CAS#: 84774-03-8
Chemical Formula:
Exact Mass: 0.00
Molecular Weight: 0.000
Elemental Analysis:

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Mrz 2549; Mrz-2549; Mrz2549

IUPAC/Chemical Name: 2,6-Methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-3-(2-methoxypropyl)-6,11-dimethyl-

InChi Key: OYOSCGNGSBDVQJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H27NO2/c1-12(21-4)11-19-8-7-18(3)13(2)17(19)9-14-5-6-15(20)10-16(14)18/h5-6,10,12-13,17,20H,7-9,11H2,1-4H3

SMILES Code: OC1=CC=C2C(C3(C)CCN(CC(OC)C)C(C3C)C2)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 0.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991 Apr;128(4):2027-35. doi: 10.1210/endo-128-4-2027. PMID: 2004615.


2: Hassen AH, Feuerstein G, Faden AI. Kappa opioid receptors modulate cardiorespiratory function in hindbrain nuclei of rat. J Neurosci. 1984 Sep;4(9):2213-21. doi: 10.1523/JNEUROSCI.04-09-02213.1984. PMID: 6148384; PMCID: PMC6564800.


3: Huffman RD, Frey JM. Response of rat globus pallidus neurons to microintophoretically applied mu and kappa opioid receptor agonists. Eur J Pharmacol. 1989 Nov 7;170(3):179-91. doi: 10.1016/0014-2999(89)90538-4. PMID: 2575994.


4: Pfeiffer DG, Pfeiffer A, Almeida OF, Herz A. Opiate suppression of LH secretion involves central receptors different from those mediating opiate effects on prolactin secretion. J Endocrinol. 1987 Sep;114(3):469-76. doi: 10.1677/joe.0.1140469. PMID: 2822829.


5: Wüster M, Rubini P, Schulz R. The preference of putative pro-enkephalins for different types of opiate receptors. Life Sci. 1981 Sep 21;29(12):1219-27. doi: 10.1016/0024-3205(81)90226-5. PMID: 6117777.


6: Hassen AH, Feuerstein G, Faden AI. Differential cardiovascular effects mediated by mu and kappa opiate receptors in hindbrain nuclei. Peptides. 1983 Sep-Oct;4(5):621-5. doi: 10.1016/0196-9781(83)90007-4. PMID: 6318199.


7: Sartor O, Bowers CY, Reynolds GA, Momany FA. Variables determining the growth hormone response of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the rat. Endocrinology. 1985 Oct;117(4):1441-7. doi: 10.1210/endo-117-4-1441. PMID: 4029086.


8: Pfeiffer A, Herz A, Loriaux DL, Pfeiffer DG. Central kappa- and mu-opiate receptors mediate ACTH-release in rats. Endocrinology. 1985 Jun;116(6):2688-90. doi: 10.1210/endo-116-6-2688. PMID: 2986960.


9: Ensinger HA, Doevendans JE. Plasma levels of opioid analgesics determined by radioreceptor assay. Arzneimittelforschung. 1984;34(5):609-13. PMID: 6540579.


10: Heath RG, Fitzjarrell AT, Walker CF. Kappa opiate receptor agonists: effects on behavior and on brain function and structure in rhesus monkeys. Biol Psychiatry. 1984 Jul;19(7):1045-74. PMID: 6089918.